Jubilant Pharmova Ltd Q1 FY27 Earnings Analysis

- FY2027 growth momentum expected to strengthen, with overall low double-digit business growth (Harsher Singh). - Radiopharma highest margin products supply shortage causes H1 FY2027 revenue impact (~$14 million) but normalization and margin improvement expected in H2 FY2027; margins of 17-18% anticipated (Arun Kumar Sharma, Harsher Singh). - Line 3 tech transfer revenues to generate $60-$80 million in FY2027 with margin improvements expected post full utilization (Chris Preti). - Allergy business growth driven by higher non-US volumes, greater US market share, and expansion in Europe; US allergy segment approx. 90% of business (Priyavrat Bhartia, Anuj Mohnot). - Ruby-Fill® franchise growing ~30%+, supported by a growing market and increasing market share (Harsher Singh). - Montreal plant production stabilizing by H2 FY2027; capex cycle ending FY2027 leading to free cash flow and debt reduction from FY2028 (Harsher Singh, Arun Kumar Sharma).

- FY2027 growth momentum expected to strengthen across businesses. - EBITDA margin for FY2027 to be "story of two halves": lower in H1 due to SPECT supply shortages at Montreal, improving to ~17-18% in H2 as production stabilizes. - FY2028 onwards, margins expected to normalize and improve with full ramp-up of Montreal production. - Radiopharma business expected to grow in low double digits in FY2027 with margins in 38%-40% range. - CDMO sterile injectable (Line 3 and Line 4) expected to contribute higher revenue and improve margins progressively from FY2027 onwards. - Free cash flow generation expected from FY2027 with commercialization ramp-up, aiding debt reduction aimed to reach net zero by FY2030. - Allergy business projected to sustain growth driven by increasing market share and expansion into non-US markets. - Overall, earnings and profitability expected to improve steadily post-FY2027 with growth and margin expansion across segments.

- FY2026 capex was Rs.1,668 Crores; FY2027 capex expected to be similar. - Key ongoing projects include: - Spokane Line 4: $34 million pending of ~$200 million total. - Montreal Line 5: $87 million pending of $114 million total. - PET pharmacies: $50 million pending of $72 million total. - No anticipated new capex beyond the above four major investments (Line 3, Line 4, Line 5, PET manufacturing) in the next 12-18 months. - Capital allocation guided by ROCE threshold to ensure investments are accretive. - Post FY2027, expect free cash flow from commercial production on Line 3 and tech transfers on Line 4, aiding debt reduction. - Committed to achieving net debt zero by FY2030 with deleveraging expected from FY2028 onwards.

- The company has a significant ongoing capex cycle through FY2027, including investments in Spokane Line 4, Montreal Line 5, and PET pharmacies. - FY2027 capex is expected to be similar to FY2026 (~Rs.1,668 Crores), with no mention of new fundraising rounds. - Management highlighted commitment to reducing net debt starting FY2028 and achieving net debt zero by FY2030. - Capital allocation is governed by a Return on Capital Employed (ROCE) threshold; only capital investments crossing this threshold are approved. - No additional capex over the next 12-18 months beyond existing projects is anticipated, indicating no immediate need for new funding. - Debt is currently at Rs.1,952 crore as of FY2026. - Overall, no explicit mention of fresh fundraising through debt or equity in the near term; focus is on deleveraging as projects start generating cash flow.

The transcript does not provide explicit details on the current or expected order book or pending orders for Jubilant Pharmova Limited. However, relevant insights related to the product pipeline and production capacity include: - The CDMO Sterile Injectables segment has approximately 10+ products undergoing tech transfer for Line 3, with commercial production expected in late FY2027. - Among these, about 80% are complex biologics, including one of the world's largest oncology products. - Line 3 is projected to reach peak revenue of $80-90 million one-and-a-half to two years earlier than initially projected. - The Radiopharma segment is ramping up with new PET pharmacies planned for commercialization next year. - Ruby-Fill® installations are growing strongly in the US, with increasing market share and pricing momentum. - Allergy business growth driven by higher volumes in non-US markets and market share gain in the US. No direct quantitative order backlog or pending order figures are disclosed in the transcript.